Navigation Links
Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
Date:10/1/2007

ectable virus 24 weeks after stopping therapy, which clevudine previously demonstrated in Bukwang's South Korean registration studies.

At week 72, HBeAg- patients in Study 306 who have been treated with clevudine and have suppressed HBV DNA and normalized ALT levels will be randomized to continue active clevudine or switch to placebo. The purpose is to determine the proportion of patients who sustain a virologic response 24 weeks after stopping clevudine treatment at week 96. HBeAg+ patients in Study 305 that have been treated with either clevudine or Hepsera and undergo eAg seroconversion (loss of eAg with suppressed HBV DNA and normalized ALT) will discontinue therapy at week 72. SVR will be assessed in these HBeAg+ patients for clevudine and Hepsera 24 weeks after stopping treatment at week 96.

South Korean Registration Studies for Clevudine

Bukwang received marketing approval for clevudine from the South Korean FDA based on two 24-week, randomized (3:1), double-blind, placebo-controlled, multi-center South Korean Phase 3 registration trials in 337 patients. Study 301 enrolled 248 HBeAg+ patients who received clevudine 30 mg or a placebo once-daily, and Study 302 enrolled 89 HBeAg- patients who received clevudine 30 mg or a placebo once-daily. All patients were evaluated for an additional 24 weeks of follow-up care without clevudine treatment.

After 24 weeks of clevudine treatment, 59% of HBeAg+ patients achieved undetectable HBV DNA (<300 copies/mL) and 92% of HBeAg- patients achieved undetectable HBV DNA. These results were statistically significant compared to placebo. In addition to the potent antiviral suppression, 16% of the HBeAg- patients who received clevudine demonstrated a sustained virologic response (SVR) 24 weeks after stopping therapy, versus 0% of the patients who had received the placebo. In Study 303, a South Korean open-label, follow-on study of clevudine, Bukwang observed similar findings to those noted above for Studie
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014   BioNano Genomics announced today achievement of ... collect human data at 30X depth, sufficient for a genome ... capability was established and demonstrated for the IrysChip TM ... System and will be rolled out to BioNano,s collaborators ... showcasing this advancement at the American Society for Human ...
(Date:10/20/2014)... 2014 Pharmaceutic Labs announces the opening of ... Albany, NY for admixing, compounding, drug shortages ... exceeds the FDA standards for safety and quality, using ... The 10,000 square foot outsourcing facility ... assurance and quality control. The company will produce sterile ...
(Date:10/19/2014)... 20, 2014 Shire plc (LSE: SHP, NASDAQ: ... Chief Financial Officer (CFO), has notified the Board of Directors of ... a new career opportunity as CFO of Severn Trent plc.  James ... company will commence a search for a new CFO immediately. ... has helped build and lead a high-quality finance team at Shire. ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... ANTONIO, Oct. 6 Nautilus Neurosciences, Inc., ... Pharmacal Company, a privately-held pharmaceutical company focused ... their exclusive co-promotion agreement for CAMBIA™ (diclofenac ... and other women,s health medical professionals. CAMBIA™ ...
... Gerresheimer Reports Strong Earnings and Sales Growth -- DUSSELDORF, Germany, October 6, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4Gerresheimer Reports Strong Earnings and Sales Growth 2Gerresheimer Reports Strong Earnings and Sales Growth 3Gerresheimer Reports Strong Earnings and Sales Growth 4Gerresheimer Reports Strong Earnings and Sales Growth 5Gerresheimer Reports Strong Earnings and Sales Growth 6Gerresheimer Reports Strong Earnings and Sales Growth 7Gerresheimer Reports Strong Earnings and Sales Growth 8Gerresheimer Reports Strong Earnings and Sales Growth 9
(Date:10/20/2014)... Fort Collins, CO (PRWEB) October 20, 2014 ... platform, dGH assays are the only imaging assays ... data in a single test.  With these three ... in their ability to detect the widest range ... chromosomal translocations—mutations usually missed by other genomic tools, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Unveiled at the ... Strategic Direction Scorecard conservatively estimates member hospital ROI on membership ... on dues, The Center provides $12.50 in value to member ... (Member Value – Member Dues)/Member Dues. , “This is ... this number and we think the methodology is really sound,” ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... running, jogging on physical health have been known for a ... Germany that running can improve the mental health status as ... // ,The study participants had to complete a minimum of ... had to take up progressively difficult tests. The researchers examined ...
... has been lifted on account of no single case of bird ... racing, falconry and other bird shows were regularly conducted in Britain.// ... which was detected in Eastern Europe the events were banned to ... of bird flu was reported the health officials are planning to ...
... of two drugs in a rare medical trail. These drugs ... ,They are anti-retroviral drugs which have been studied individually ... are unapproved for the usage in AIDS patient and hence ... usage of this new unapproved AIDS drug started nine months ...
... human cancer cells in a unique way will be ... Zealand. The clinical trial would be held at New ... on Wednesday. ,Auckland University cancer researcher Professor Bill ... is converted to a DNA damaging agent in the ...
... treatment of Ambylopia or lazy eye as it is commonly called. ... at the USC and three other Chinese universities. //,A ... compromise in the vision even when corrective glasses are used. If ... condition has been regarded to be incurable in children over 8 ...
... says that elderly white women who have had non-melanoma skin ... of their exposure to the harmful rays of the sun. ... age group of 50 to 79, who had a previous ... the skin, had a two-fold increase in the risk of ...
Cached Medicine News:Health News:Health Canada Gave Access To Unapproved Drugs To AIDS/HIV Patients. 2
... Our new oversized wheelchair scales incorporate all ... model including automatic zero, weight recall, reweigh ... displays weight in pounds and kilos., ... patients in electric and oversized wheelchairs. The ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... Endo-PAT2000 is a simple and easy to ... PAT signal is recorded using Itamar Medical's ... is analyzed automatically using proprietary advanced Digital ... within seconds of completing the test. The ...
... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...
Medicine Products: